What We're Reading: Page 139
Industry reads hand-picked by our editors
Sep 15, 2021
-
Bloomberg Government
Drug Pricing Opponents Complicate Democrats' Health Ambitions
-
Nature
The tangled history of mRNA vaccines
-
FierceBiotech
Sanofi dumps Principia Biopharma's San Francisco labs with plans to immediately cut 38 jobs
-
Evaluate Vantage
Front-line competition lines up behind Keytruda
Sep 14, 2021
-
Evaluate Vantage
Esmo 2021 – Mirati bids to be belle of the ball
-
The Wall Street Journal
After Covid-19 Data Is Deleted, NIH Reviews How Its Gene Archive Is Handled
-
C&EN
A sizzling biotech job market is streamlining the course to a career in chemistry
-
Reuters
WHO-backed vaccine hub for Africa to copy Moderna COVID-19 shot
Sep 13, 2021
-
BioCentury
Fred Frank, co-founder of the biotech industry, is dead at 89
-
Reuters
Britain begins world's largest trial of blood test for 50 types of cancer
-
STAT
A vaccine veteran steps away from the NIH, looking out toward the world
-
FiercePharma
Bausch pays whopping $300M to settle Glumetza pay-for-delay lawsuit after 800% price hike
Sep 10, 2021
-
Associated Press
Sweeping new vaccine mandates for 100 million Americans
-
The Wall Street Journal
Theranos Trial Paused Over Possible Juror Covid-19 Exposure
-
The Economist
Why scientists are deliberately infecting volunteers with Covid-19
-
Endpoints News
Martin Shkreli to go toe-to-toe with new FTC chair over Daraprim price spikes
Sep 09, 2021
-
The Wall Street Journal
White House Unveils Plan to Cut Prescription-Drug Prices
-
STAT
FDA rejection of Humanigen drug points to industry challenge in Covid fight
-
Evaluate Vantage
Centessa takes a step towards a new hemophilia mechanism
Sep 08, 2021
-
Bloomberg
Feared Wall Street Fund Elliott Is Targeting GSK. What Does It Want?
-
FierceBiotech
SPAC Attack: The 10 biggest in biotech
-
Financial Times
Top Pfizer scientist defends Covid vaccine booster push and jab’s potency
-
Smithsonian Magazine
Frog Foam May Help Deliver Drugs to Human Skin
Sep 07, 2021
-
Bloomberg
One Vaccine Makes More Antibodies Than Another. Does it Matter?
-
MIT Technology Review
Meet Altos Labs, Silicon Valley’s latest wild bet on living forever
-
FiercePharma
Crippled by opioid-crisis litigation, Mallinckrodt settlement brings company closer to reorganization
-
STAT
CEPI warns of major hurdle to developing new Covid-19 vaccines
Previous
